• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BNO
Click for more information
5.26% 20.0¢

BIONOMICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
BNO Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
BNO Bionomics to Feature at 2016 San Francisco Biotech Showcase11/01/16
BNO Change of Director's Interest Notice30/12/15
BNO Change of Director's Interest Notice30/12/15
BNO Appendix 3B30/12/15
BNO Ceasing to be a substantial holder21/12/15
BNO Letter to Shareholders17/12/15
BNO Change of Director's Interest Notice16/12/15
BNO Ceasing to be a substantial holder14/12/15
BNO Cleansing Notice10/12/15
BNO Appendix 3B10/12/15
BNO BNC210 Post Traumatic Stress Disorder Trial & Capital RaisePRICE SENSITIVE08/12/15
BNO Trading HaltPRICE SENSITIVE04/12/15
BNO Appendix 3B30/11/15
BNO Final Director's Interest Notice19/11/15
BNO Annual General Meeting 2015 Results18/11/15
BNO CEO & Managing Directors AGM Presentation 201518/11/15
BNO Chairman's Address Bionomics Annual General Meeting 201518/11/15
BNO BNO and MSD Alzheimer's Disease Symposium13/11/15
BNO Appendix 3B11/11/15
BNO Appendix 3B06/11/15
BNO Appendix 3B05/11/15
BNO Appendix 3B04/11/15
BNO NEW BNC105 DATA TO BE PRESENTED IN U.S.PRICE SENSITIVE04/11/15
BNO Appendix 3B03/11/15
BNO Appendix 4C - quarterlyPRICE SENSITIVE30/10/15
BNO Becoming a substantial holder28/10/15
BNO Change of Director's Interest Notice21/10/15
BNO Appendix 3B21/10/15
BNO Appendix 4G / Corporate Governance Statement16/10/15
BNO Bionomics Annual Report 201516/10/15
BNO Notice of Annual General Meeting/Proxy Form16/10/15
BNO Cleansing Notice12/10/15
BNO Appendix 3B12/10/15
BNO Investor Conference Call Details08/10/15
BNO Merck Investment and Pain Partnership ExtendedPRICE SENSITIVE08/10/15
BNO Initial Director's Interest Notice29/09/15
BNO Bionomics Appoints Dr. Alan W. Dunton to Board of Directors29/09/15
BNO Change of Director's Interest Notice25/09/15
BNO Appendix 3B23/09/15
BNO Ceasing to be a substantial holder17/09/15
BNO BNO Reports Positive Data From BNC210 Clinical TrialPRICE SENSITIVE16/09/15
BNO BNC101 FDA SUBMISSION SUCCESSFULPRICE SENSITIVE31/08/15
BNO Full Year Statutory Accounts10/08/15
BNO Bionomics 2014/2015 Preliminary Final ResultsPRICE SENSITIVE10/08/15
BNO Bionomics Strengthens Management Team03/08/15
BNO Appendix 4C - quarterlyPRICE SENSITIVE31/07/15
BNO Appendix 3B24/07/15
BNO Bionomics Corporate Presentation July 201523/07/15
BNO Appendix 3B30/06/15
BNO Appendix 3B18/06/15
BNO BNC105 Enhances Efficacy of Immuno-Oncology TherapiesPRICE SENSITIVE15/06/15
BNO Bionomics NOW May 2015 Newsletter27/05/15
BNO Bionomics ASX Spotlight Corporate Presentation26/05/15
BNO Appendix 3B25/05/15
BNO Bionomics Strengthens Leadership Team18/05/15
BNO Change of Director's Interest Notice05/05/15
BNO Appendix 3B05/05/15
BNO Appendix 4C - quarterlyPRICE SENSITIVE30/04/15
BNO Appendix 3B27/04/15
BNO Bionomics Initiates Phase II BNC210 Clinical TrialPRICE SENSITIVE20/04/15
BNO Bionomics Showcases Oncology Programs at AACR Annual Meeting17/04/15
BNO Change of Director's Interest Notice15/04/15
BNO Appendix 3B15/04/15
BNO BNC105 Biomarker Data Presented at Asian Oncology Summit10/04/15
BNO Appendix 3B30/03/15
BNO Appendix 3B05/03/15
BNO Bionomics 2015 Corporate Presentation - February 201503/03/15
BNO Bionomics begins trading on OTCQX marketplace02/03/15
BNO Bionomics to present at upcoming March US Conferences27/02/15
BNO BNC105 NEW DATAPRICE SENSITIVE27/02/15
BNO Half Yearly Report and AccountsPRICE SENSITIVE23/02/15
BNO Appendix 3B16/02/15
BNO Bionomics Begins Phase 1B Study With Anxiety Drug BNC210PRICE SENSITIVE02/02/15
BNO Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
BNO Bionomics NOW January 2015 Newsletter12/01/15
BNO Bionomics CEO to Present at Biotech Showcase12/01/15
BNO Bionomics CEO to Present at Biotech Showcase12/01/15
BNO Change of Director's Interest Notice04/12/14
BNO Appendix 3B04/12/14
BNO Appendix 3B26/11/14
BNO Change of Director's Interest Notice24/11/14
BNO Amended Change of Director's Interest Notice20/11/14
BNO BNC101 Data Presented at European Cancer Conference20/11/14
BNO Change of Director's Interest Notice18/11/14
BNO Appendix 3B18/11/14
BNO Change of Director's Interest Notice18/11/14
BNO BNC210 Data To Be Presented At US Conference17/11/14
BNO Annual General Meeting 2014 Results12/11/14
BNO CEO & Managing Director's AGM Presentation 201412/11/14
BNO Bionomics To Progress BNC210 In Clinical TrialsPRICE SENSITIVE11/11/14
BNO Appendix 4C - quarterlyPRICE SENSITIVE31/10/14
BNO Appendix 3B16/10/14
BNO BNC105 Data In International Peer-Reviewed Cancer JournalPRICE SENSITIVE14/10/14
BNO Notice of Annual General Meeting/Proxy Form10/10/14
BNO Bionomics Annual Report 201410/10/14
BNO Correction - BNC105 Phase II Trial Biomarker Data29/09/14
BNO BNO Presents BNC105 Phase II Trial Biomarker DataPRICE SENSITIVE29/09/14
BNO Bionomics Investor Presentation23/09/14
BNO Bionomics Acquires Prestwick ChemicalPRICE SENSITIVE23/09/14
BNO Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
BNO Bionomics to Feature at 2016 San Francisco Biotech Showcase
11/01/16
BNO Change of Director's Interest Notice
30/12/15
BNO Change of Director's Interest Notice
30/12/15
BNO Appendix 3B
30/12/15
BNO Ceasing to be a substantial holder
21/12/15
BNO Letter to Shareholders
17/12/15
BNO Change of Director's Interest Notice
16/12/15
BNO Ceasing to be a substantial holder
14/12/15
BNO Cleansing Notice
10/12/15
BNO Appendix 3B
10/12/15
BNO BNC210 Post Traumatic Stress Disorder Trial & Capital Raise
08/12/15PRICE SENSITIVE
BNO Trading Halt
04/12/15PRICE SENSITIVE
BNO Appendix 3B
30/11/15
BNO Final Director's Interest Notice
19/11/15
BNO Annual General Meeting 2015 Results
18/11/15
BNO CEO & Managing Directors AGM Presentation 2015
18/11/15
BNO Chairman's Address Bionomics Annual General Meeting 2015
18/11/15
BNO BNO and MSD Alzheimer's Disease Symposium
13/11/15
BNO Appendix 3B
11/11/15
BNO Appendix 3B
06/11/15
BNO Appendix 3B
05/11/15
BNO Appendix 3B
04/11/15
BNO NEW BNC105 DATA TO BE PRESENTED IN U.S.
04/11/15PRICE SENSITIVE
BNO Appendix 3B
03/11/15
BNO Appendix 4C - quarterly
30/10/15PRICE SENSITIVE
BNO Becoming a substantial holder
28/10/15
BNO Change of Director's Interest Notice
21/10/15
BNO Appendix 3B
21/10/15
BNO Appendix 4G / Corporate Governance Statement
16/10/15
BNO Bionomics Annual Report 2015
16/10/15
BNO Notice of Annual General Meeting/Proxy Form
16/10/15
BNO Cleansing Notice
12/10/15
BNO Appendix 3B
12/10/15
BNO Investor Conference Call Details
08/10/15
BNO Merck Investment and Pain Partnership Extended
08/10/15PRICE SENSITIVE
BNO Initial Director's Interest Notice
29/09/15
BNO Bionomics Appoints Dr. Alan W. Dunton to Board of Directors
29/09/15
BNO Change of Director's Interest Notice
25/09/15
BNO Appendix 3B
23/09/15
BNO Ceasing to be a substantial holder
17/09/15
BNO BNO Reports Positive Data From BNC210 Clinical Trial
16/09/15PRICE SENSITIVE
BNO BNC101 FDA SUBMISSION SUCCESSFUL
31/08/15PRICE SENSITIVE
BNO Full Year Statutory Accounts
10/08/15
BNO Bionomics 2014/2015 Preliminary Final Results
10/08/15PRICE SENSITIVE
BNO Bionomics Strengthens Management Team
03/08/15
BNO Appendix 4C - quarterly
31/07/15PRICE SENSITIVE
BNO Appendix 3B
24/07/15
BNO Bionomics Corporate Presentation July 2015
23/07/15
BNO Appendix 3B
30/06/15
BNO Appendix 3B
18/06/15
BNO BNC105 Enhances Efficacy of Immuno-Oncology Therapies
15/06/15PRICE SENSITIVE
BNO Bionomics NOW May 2015 Newsletter
27/05/15
BNO Bionomics ASX Spotlight Corporate Presentation
26/05/15
BNO Appendix 3B
25/05/15
BNO Bionomics Strengthens Leadership Team
18/05/15
BNO Change of Director's Interest Notice
05/05/15
BNO Appendix 3B
05/05/15
BNO Appendix 4C - quarterly
30/04/15PRICE SENSITIVE
BNO Appendix 3B
27/04/15
BNO Bionomics Initiates Phase II BNC210 Clinical Trial
20/04/15PRICE SENSITIVE
BNO Bionomics Showcases Oncology Programs at AACR Annual Meeting
17/04/15
BNO Change of Director's Interest Notice
15/04/15
BNO Appendix 3B
15/04/15
BNO BNC105 Biomarker Data Presented at Asian Oncology Summit
10/04/15
BNO Appendix 3B
30/03/15
BNO Appendix 3B
05/03/15
BNO Bionomics 2015 Corporate Presentation - February 2015
03/03/15
BNO Bionomics begins trading on OTCQX marketplace
02/03/15
BNO Bionomics to present at upcoming March US Conferences
27/02/15
BNO BNC105 NEW DATA
27/02/15PRICE SENSITIVE
BNO Half Yearly Report and Accounts
23/02/15PRICE SENSITIVE
BNO Appendix 3B
16/02/15
BNO Bionomics Begins Phase 1B Study With Anxiety Drug BNC210
02/02/15PRICE SENSITIVE
BNO Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
BNO Bionomics NOW January 2015 Newsletter
12/01/15
BNO Bionomics CEO to Present at Biotech Showcase
12/01/15
BNO Bionomics CEO to Present at Biotech Showcase
12/01/15
BNO Change of Director's Interest Notice
04/12/14
BNO Appendix 3B
04/12/14
BNO Appendix 3B
26/11/14
BNO Change of Director's Interest Notice
24/11/14
BNO Amended Change of Director's Interest Notice
20/11/14
BNO BNC101 Data Presented at European Cancer Conference
20/11/14
BNO Change of Director's Interest Notice
18/11/14
BNO Appendix 3B
18/11/14
BNO Change of Director's Interest Notice
18/11/14
BNO BNC210 Data To Be Presented At US Conference
17/11/14
BNO Annual General Meeting 2014 Results
12/11/14
BNO CEO & Managing Director's AGM Presentation 2014
12/11/14
BNO Bionomics To Progress BNC210 In Clinical Trials
11/11/14PRICE SENSITIVE
BNO Appendix 4C - quarterly
31/10/14PRICE SENSITIVE
BNO Appendix 3B
16/10/14
BNO BNC105 Data In International Peer-Reviewed Cancer Journal
14/10/14PRICE SENSITIVE
BNO Notice of Annual General Meeting/Proxy Form
10/10/14
BNO Bionomics Annual Report 2014
10/10/14
BNO Correction - BNC105 Phase II Trial Biomarker Data
29/09/14
BNO BNO Presents BNC105 Phase II Trial Biomarker Data
29/09/14PRICE SENSITIVE
BNO Bionomics Investor Presentation
23/09/14
BNO Bionomics Acquires Prestwick Chemical
23/09/14PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play Asian Battery Metals Plc has hit another massive sulphide intercept at the North Oval area of its Oval project in Mongolia
iTech inks deal with Chilean lithium giant to progress Reynolds Range iTech Minerals Ltd has signed a deal which will allow for the development of its Reynolds Range lithium project
IP anomaly thrills Cannidah with project extension hopes in QLD Cannidah Resources has carried out geophysical work at its flagship project in Queensland which highlighted an IP anomaly.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.